Literature DB >> 28936459

Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC.

Kyrillus S Shohdy1, Omar Abdel-Rahman2.   

Abstract

Entities:  

Year:  2017        PMID： 28936459      PMCID： PMC5599297          DOI： 10.21037/atm.2017.06.67

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  7 in total

1.  Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  Ther Adv Respir Dis       Date:  2016-03-04       Impact factor: 4.031

Review 2.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Authors:  Monica Khunger; Sagar Rakshit; Vinay Pasupuleti; Adrian V Hernandez; Peter Mazzone; James Stevenson; Nathan A Pennell; Vamsidhar Velcheti
Journal:  Chest       Date:  2017-05-10       Impact factor: 9.410

Review 3.  Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy.

Authors:  Jennifer D Possick
Journal:  Clin Chest Med       Date:  2017-06       Impact factor: 2.878

4.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Authors:  Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

5.  Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.

Authors:  Tzu-Rong Peng; Fang-Pei Tsai; Ta-Wei Wu
Journal:  Int Immunopharmacol       Date:  2017-05-27       Impact factor: 4.932

Review 6.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 7.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

Authors:  Mizuki Nishino; Anita Giobbie-Hurder; Hiroto Hatabu; Nikhil H Ramaiya; F Stephen Hodi
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777
  7 in total
  6 in total

1.  Pulmonary Toxicities of Immunotherapy.

Authors:  Mehmet Altan; Linda Zhong; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Immune-Related Adverse Events: Pneumonitis.

Authors:  Linda Zhong; Mehmet Altan; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.

Authors:  Makoto Nishio; Haruhiro Saito; Koichi Goto; Satoshi Watanabe; Naoko Sueoka-Aragane; Yusuke Okuma; Kazuo Kasahara; Kenichi Chikamori; Yuki Nakagawa; Tomohisa Kawakami
Journal:  Cancer Sci       Date:  2021-02-09       Impact factor: 6.716

4.  Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?

Authors:  Hannah M T Thomas; Daniel S Hippe; Parisa Forouzannezhad; Balu Krishna Sasidharan; Paul E Kinahan; Robert S Miyaoka; Hubert J Vesselle; Ramesh Rengan; Jing Zeng; Stephen R Bowen
Journal:  Discov Oncol       Date:  2022-09-01

Review 5.  The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review.

Authors:  Alistair R Miller; Renee Manser
Journal:  Transl Lung Cancer Res       Date:  2021-06

6.  Pulmonary Complications Secondary to Immune Checkpoint Inhibitors.

Authors:  Hasan Ahmad Hasan Albitar; Narjust Duma; Konstantinos Leventakos; Alice Gallo De Moraes
Journal:  Int J Chronic Dis       Date:  2020-04-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.